E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Physiological processes [G07] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10003639 |
E.1.2 | Term | Atopic dermatitis |
E.1.2 | System Organ Class | 100000004858 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
We hypothesise that use of TCS elicits insulin resistance and increases bone resorption (indicating increased risk of osteoporosis) in AD patients. The aim is, therefore, to explore the adverse systemic drug reactions of TCS. Specifically, we aim to 1. evaluate whether full-body TCS treatment results in hepatic and/or whole-body insulin resistance (the forerunner of T2D) as well as increased bone resorption (indicating increased risk of osteoporosis) in patients with AD 2. evaluate the effect of TCS on skin and serum biomarkers of skin barrier function as well as skin microbiome composition |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inclusion criteria • Age 18–75 years • AD according to the Hanifin and Rajka Criteria22 • AD for at least 3 years • BMI ≤ 30 kg/m2 • Haemoglobin A1c (HbA1c) ≤ 42 mmol/mol (6.0%) • Normal haemoglobin • Informed consent |
|
E.4 | Principal exclusion criteria |
Exclusion criteria • Diagnosed diabetes mellitus • Other chronic inflammatory diseases (including but not limited to rheumatoid arthritis, inflammatory bowel disease etc) beside AD and non-treatment demanding rhinitis or asthma (treated within the last 4 weeks) • Pregnancy or breast feeding • Treatment with drugs that might affect the glucose metabolism beside TCS within a month prior to the project • Daily smoker, alcoholic, or drug abuser |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is change in whole-body insulin sensitivity during treatment with TCS compared to the control group treated with TCI. Insulin sensitivity will be assessed by the hyperinsulinaemic euglycaemic clamp method with glucose tracer and indirect calorimetry (rate of disappearance (Rd)). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
After all patients have completed the study and samples are analysed. |
|
E.5.2 | Secondary end point(s) |
Key secondary endpoints are markers of bone resorption and formation including C-terminal telopeptide of type I collagen (CTX), N-terminal propeptide of type 1 procollagen (P1NP) and parathyroid hormone (PTH), respectively, and body composition (assessed by dual-energy X-ray absorptiometry (DXA) scan).
Other secondary endpoints include differences between patients treated with TCS and TCI controls during basal and insulin-stimulated steady-state in: • Glucose oxidation (assessed by indirect calorimetry) • Non-oxidative glucose metabolism (NOGM) • Endogenous glucose production (calculated from glucose tracer data) • Lipid oxidation (assessed by indirect calorimetry) • Insulin resistance according to the homeostatic model assessment (HOMA-IR) index • Beta cell function (assessed by arginine-stimulation test)
Differences between patients treated with TCS and TCI matched controls in: • Serum/plasma concentrations of insulin, C-peptide, glucagon, free fatty acids (FFA), high sensitivity C-reactive protein (hsCRP), interleukin 6 (IL-6), tumor necrosis factor-α (TNF-α) • Liver status (assessed by plasma levels of transaminases and fibro scanning) • Assessment of internal corticosteroid exposure by urine sampling and skin tape striping that will undergo analysis with high-performance liquid chromatography (HPLC). • Skin barrier status and possible differential improvement and effects (assessed using skin tape strip analysis for amino acids (filaggrin degradation products), and inflammatory biomarkers of relevance to AD (including but not limited to CCL-17, IL-1, IL-4, IL-13, IL-22) • Analysis of T-cell phenotype by flow cytometry and single cell sequencing • Microbiome analysis: Investigation of different treatment effects on the composition of skin bacteria (assessed using skin and nasal swaps for sequencing bacterial microbiome DNA) • AD severity (evaluated by VAS for itch intensity and sleep disturbance, EASI, DLQI, POEM • Transepidermal water loss • Level of physical activity (assessed by IPAQ) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
After all patients have completed the study and blood, urine and skin samples are analysed. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Side effects from full-body topical corticosteroid treatment. |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS When 36 patients have completed the study.
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |